 |
328 Diseases |  |
113 Trials |
|
113 Trials |  |
9098 News |  |
| 12345678910111213...109110» |
- | erlotinib / Generic mfg., gefitinib / Generic mfg.
Journal: In silico analysis, isolation, and cytotoxicity evaluation of the coumestans from Cullen corylifolium (L.) Medik. (Pubmed Central) - Nov 18, 2024
The best hit, compound 1 was evaluated for its cytotoxicity against MDA-MB-231 and A549 cells via in vitro assay. The ligand-protein complex exhibited good stability, binding free energies, better in silico pharmacokinetics, low toxicity, and good cytotoxicity.
- || Clinical, Retrospective data, Review, Journal: Risk of treatment-related toxicity from EGFR tyrosine kinase inhibitors: a systematic review and network meta-analysis of randomized clinical trials in EGFR-mutant non-small cell lung cancer. (Pubmed Central) - Nov 18, 2024
Difference in safety between the third-generation EGFR-TKIs was also first investigated comprehensively. Furthermore, this review elaborated the varied predominate spectrum and ranked the toxicity of EGFR-TKIs for providing toxicity rationale for treatment decisions.
- | Tagrisso (osimertinib) / AstraZeneca, Gilotrif (afatinib) / Boehringer Ingelheim
Journal: Aderenza e persistenza come indicatori di esito in tempo reale dei trattamenti farmacologici oncoematologici e il caso degli anti-EGFR in prima linea nello NSCLC. (Pubmed Central) - Nov 18, 2024
We analysed data of first and second generation drugs (afatinib, gefitinib, erlotinib) and the new third generation drug (osimertinib). Median Ttd and adherence as Proportion of days covered (Pdc) were respectively 11.6 versus 23.4 months and 0.92 versus 0.95.
- | Journal: Pyrazole, Pyrazoline, and Fused Pyrazole Derivatives: New Horizons in EGFR-Targeted Anticancer Agents. (Pubmed Central) - Nov 16, 2024
Several drugs include the pyrazole scaffold, such as ramifenazone, ibipinabant, antipyrine, and axitinib, etc. They have been extensively studied by the scientific community and are said to have a wide range of biological activity, especially anticancer agents targeting EGFR...Several anti-EGFR drugs are thriving, notably dacomitinib, afatinib, erlotinib, gefitinib, and osimertinib...The current review outlines the investigation of advancements towards anti- EGFR via pyrazole, pyrazoline, and fused pyrazole-based compounds and represents inclusive data on pyrazole-based marketed drugs as well as therapeutic candidates undergoing preclinical and clinical development. We have also summarised structure-activity relationship (SAR), mechanistic studies to afford ideas for the design and development of new anti-EGFR derivatives.
- | gefitinib / Generic mfg.
Journal: Integrated microbiome and metabolome analysis reveals synergistic efficacy of basil polysaccharide and gefitinib in lung cancer through modulation of gut microbiota and fecal metabolites. (Pubmed Central) - Nov 16, 2024
Our findings indicate that BPS can enhance tumor responsiveness to gefitinib by modulating the gut microbiota and its metabolites through multiple metabolic pathways. These changes in gut microbiota and metabolites could potentially affect cancer related signaling pathway and lung resistance-related protein, which are pivotal in determining the efficacy of EGFR-TKIs in cancer treatment.
- | erlotinib / Generic mfg.
Journal: Erlotinib and curcumin-loaded nanoparticles embedded in thermosensitive chitosan hydrogels for enhanced treatment of head and neck cancer. (Pubmed Central) - Nov 16, 2024
In vivo studies conducted on a xenograft HNSCC mouse model revealed the significant capacity of the intratumorally-injected optEr/Cm-NP-HG21 formulation to retard the tumor growth. Conclusively, the results presented herein report the successful development of a nanocomposite HG system incorporating NPs co-loaded with Er and Cm that could be efficiently utilized in the treatment of HNSCC.
- || Clinical, Journal, Metastases: Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01. (Pubmed Central) - Nov 13, 2024
Conclusively, the results presented herein report the successful development of a nanocomposite HG system incorporating NPs co-loaded with Er and Cm that could be efficiently utilized in the treatment of HNSCC. Based on real-world data, osimertinib did not show a significant improvement in overall survival compared to other EGFR-TKIs as a first-line treatment for EGFR-mutated advanced non-small cell lung cancer in the Japanese (Asian) population.
- || PK/PD data, Preclinical, Journal: Development and validation of an LC-MS/MS method for simultaneous quantification of eight drugs in plasma and brain: Application in a pharmacokinetic study in mice. (Pubmed Central) - Nov 13, 2024
A selective and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantitation of a cassette of 8 drugs, including docetaxel, erlotinib, loperamide, riluzole, vemurafenib, verapamil, elacridar and tariquidar. Similarly, the precision for all compounds at three different concentration levels ranged below 15
- | Zarnestra (tipifarnib) / Kura Oncology, Rydapt (midostaurin) / Novartis, Vanflyta (quizartinib) / Daiichi Sankyo
Journal: An Innovative Telomere-associated Prognosis Model in AML: Predicting Immune Infiltration and Treatment Responsiveness. (Pubmed Central) - Nov 7, 2024
This innovative TRG scoring model demonstrates considerable predictive value for AML patient prognosis, offering valuable insights for optimizing treatment strategies and personalized medicine approaches. The identified TRGs and associated scoring models could aid in risk stratification and guide tailored therapeutic interventions in AML patients.
- | Rezdiffra (resmetirom) / Madrigal Pharma
Journal: Design and Synthesis of Dual Galectin-3 and EGFR Inhibitors Against Liver Fibrosis. (Pubmed Central) - Nov 6, 2024
There is currently only one FDA-approved drug (Resmetirom) in the market to combat liver fibrosis...Here, EGFR inhibitor erlotinib was used in a series of designed galectin-3 inhibitors after hybridization with the pharmacophore structure in reported galectin-3 inhibitors to impede hepatic stellate cells (HSCs) activation by a typical method of click chemistry...Further docking studies were performed to clarify the possible binding mode of compound 29 with galectin-3 and EGFR. Taken together, these results suggested that compound 29 could be a potential dual galectin-3 and EGFR inhibitor as leading compound for anti-liver fibrosis new drug development.
- Vectibix (panitumumab) / Amgen
Differential Efficacy of Panitumumab in Preclinical Models of Renal Medullary Carcinoma and Fumarate Hydratase-Deficient Renal Cell Carcinoma () - Nov 6, 2024 - Abstract #IKCS2024IKCS_113;
The RMC PDX model was generated from a 28-year-old male with sickle cell trait who had previously received cisplatin plus paclitaxel followed by carboplatin plus paclitaxel...The FH-deficient PDX model was generated from a 24-year-old female with HLRCC (hereditary leiomyomatosis and renal cell carcinoma syndrome), who had been previously treated with first-line bevacizumab plus erlotinib with excellent response of her metastatic disease, which allowed subsequent cytoreductive nephrectomy of the left-sided primary mass from which the PDX model was derived...We observed disease control but not tumor regression with panitumumab in our FH-deficient RCC PDX model. Based on these data, panitumumab-based therapy is currently being prospectively investigated in a multi-center cohort of patients with treatment-refractory RMC.
- dasatinib / Generic mfg.
Dasatinib Overcomes AML Resistance to BCL2 Inhibition By Indirectly Inhibiting MCL1: From Ex Vivo drug Sensitivity/Resistance Profiling to a Phase II Clinical Trial: A Hemato-BIO Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_5242;
P=N/A
On the other hand, we did not observe any anticorrelation with the EGFR-inh erlotinib nor gefitinib...DASA may be efficient in targeting VEN-R by inhibiting MCL1. Preclinical studies based on the AML collections HEMATIO-BIO allowed us to ask clinical questions that can be addressed in early-phase clinical trial.
- | Tagrisso (osimertinib) / AstraZeneca
New trial: Emulation of the FLAURA (NCT02296125) Trial Using Specialty Oncology Electronic Health Records Databases (clinicaltrials.gov) - Nov 5, 2024
P=N/A, N=4864, Active, not recruiting, Sponsor: Brigham and Women's Hospital
- || erlotinib / Generic mfg., gemcitabine / Generic mfg.
Retrospective data, Review, Journal: A meta-analysis and systematic review of randomized controlled trials in combination gemcitabine with erlotinib in the pancreatic cancer. (Pubmed Central) - Nov 4, 2024
Our study indicated that Gem-Erlo had better efficacy than gemcitabine alone in PaC therapy. The occurrence of AEs is under the acceptable range for patients.
- erlotinib / Generic mfg.
Can Artificial Intelligence Be Used to Improve the Incremental Cost Effectiveness Ratio (ICER)? Modelling Utilities as Functions of Health States in Non Small Cell Lung Cancer () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2378;
The use of ML through SR was shown in this case to improve model fit and lower the ICER as compared to standard OLS methods, while ensuring improved goodness of fit. SR, appears to improve model fit, however, is complex and requires further testing in more datasets.
- erlotinib / Generic mfg.
Can Artificial Intelligence Be Used to Improve the Incremental Cost Effectiveness Ratio (ICER): Modelling Utilities As Functions of Health States in Non Small Cell Lung Cancer by Extrapolating Beyond Trial Follow Up () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_1467;
The use of ML through SR was shown in this case to improve model fit and lower the ICER compared to standard OLS methods, while ensuring improved goodness of fit. SR, while apparently improving fit and lowering the ICER, is complex and requires further testing in more datasets.
- Avastin (bevacizumab) / Roche
Case report: Hereditary leiomyomatosis and renal cell cancer treated with bevacizumab and erlotinib (Halls 1 & 2) - Nov 3, 2024 - Abstract #COSA2024COSA_316;
With increasing use of genetic testing, there has been rapid expansion of VUS identification. Further research to understand the pathogenicity of variants would enhance clinical decision-making for management and surveillance.
- | warfarin / Generic mfg.
Preclinical, Journal: In Vitro Assessment of Inhibitory Effects of Kinase Inhibitors on CYP2C9, 3A and 1A2: Prediction of Drug-Drug Interaction Risk with Warfarin and Direct Oral Anticoagulants. (Pubmed Central) - Oct 31, 2024
Our results suggest that several kinase inhibitors, including vatalanib and linsitinib, can cause CYP-mediated drug-drug interactions with warfarin and, to a lesser extent, with apixaban and rivaroxaban. The work provides mechanistic insights into the risk of DDIs between kinase inhibitors and anticoagulants, which can be used to avoid preventable DDIs in the clinic.
- || Kinisoquin (isoquercetin) / Quercis Pharma
PK/PD data, Journal: Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with in silico pharmacokinetic and pharmacodynamic profiles. (Pubmed Central) - Oct 31, 2024
The work provides mechanistic insights into the risk of DDIs between kinase inhibitors and anticoagulants, which can be used to avoid preventable DDIs in the clinic. Tiliroside (25), boehmenan (30), boehmenan H (31), and isoquercetin (22) elicited the highest binding affinity toward the enzyme with a score of -10.4, -10.4, -10.2 and -10.1
- | mirdametinib (PD-0325901) / SpringWorks Therap, VTX-11e / Vertex, National Institutes of Health, sabutoclax (ONT-701) / Pfizer
Biomarker, Journal, Tumor mutational burden, IO biomarker: Explore the expression of mitochondria-related genes to construct prognostic risk model for ovarian cancer and validate it, so as to provide optimized treatment for ovarian cancer. (Pubmed Central) - Oct 31, 2024
In terms of drug sensitivity, the high-risk group was more sensitive to vinblastine, Acetalax, VX-11e, and PD-0325901, while the low-risk group was more sensitive to Sabutoclax, SB-505124, cisplatin, and erlotinib. The prognostic risk model of ovarian cancer associated to mitochondrial genes built on the basis of public database better evaluated the prognosis of ovarian cancer patients and guided individual treatment.
- | saracatinib (AZD0530) / AstraZeneca
Journal: A Multi-Omics Prognostic Model Capturing Tumor Stemness and the Immune Microenvironment in Clear Cell Renal Cell Carcinoma. (Pubmed Central) - Oct 26, 2024
Our findings highlight the key role of CSCs in shaping the ccRCC tumor microenvironment, crucial for therapy research and clinical guidance. Recognizing tumor stemness helps to predict treatment efficacy, recurrence, and drug resistance, informing treatment strategies and enhancing ccRCC patient outcomes.
- | Tagrisso (osimertinib) / AstraZeneca
Journal: ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors. (Pubmed Central) - Oct 26, 2024
ARAF amplification was identified in 5-8% of EGFR-TKI-resistant tumors. The possible roles of ARAF in SCLC transformation warrant further investigation.
- | sulindac / Generic mfg., erlotinib / Generic mfg.
Journal: Evaluation of EGFR and COX pathway inhibition in human colon organoids of serrated polyposis and other hereditary cancer syndromes. (Pubmed Central) - Oct 26, 2024
These findings may also facilitate clinical trial design using these agents in SPS patients. Differentially expressed genes identified in our study (MYC, FOSL1, EGR1, IL33, LGR5 and FOXQ1) may be used to identify other new molecular targets for chemoprevention of SSLs.
- | cisplatin / Generic mfg., erlotinib / Generic mfg., gefitinib / Generic mfg.
Journal, Combination therapy: Piperlongumine in combination with EGFR tyrosine kinase inhibitors for the treatment of lung cancer cells. (Pubmed Central) - Oct 25, 2024
Treatment with PPL alone and in combination induced anti-mitogenic and apoptotic responses at the molecular level. PPL sensitized lung cancer cells to EGFR-TKI and induced potent cytotoxic effects at low concentrations.
- | erlotinib / Generic mfg.
Preclinical, Journal: Precision-cut liver slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis. (Pubmed Central) - Oct 24, 2024
These results were verified in human cirrhotic PCLS. PCLS is an excellent model for assessing antifibrotic therapies that are aligned with the principles of replacement, reduction, and refinement (3Rs), and it will benefit preclinical and clinical research for human fibrosis and cirrhosis.
- | erlotinib / Generic mfg.
Journal: EGFR Inhibition by Erlotinib Rescues Desmosome Ultrastructure and Keratin Anchorage and Protects Against Pemphigus Vulgaris IgG-Induced Acantholysis in Human Epidermis. (Pubmed Central) - Oct 23, 2024
Erlotinib enhanced both single molecule DSG3 binding frequency and strength and delayed DSG3 fluorescence recovery supporting that EGFR inhibition increases DSG3 availability and cytoskeletal anchorage. Our data indicate that EGFR is a promising target for pemphigus therapy due to its link to several signaling pathways known to be involved in pemphigus pathogenesis.
- | lapatinib / Generic mfg., erlotinib / Generic mfg.
Journal, IO biomarker: Design, synthesis, and biological evaluation of novel quinoline-based EGFR/HER-2 dual-target inhibitors as potential anti-tumor agents. (Pubmed Central) - Oct 22, 2024
The apoptotic potential activity of 5a was examined, and the findings demonstrated that 5a promotes apoptosis by activating caspase-3, 8, and Bax while simultaneously reducing the expression of the anti-apoptotic protein Bcl-2. The docking studies provided valuable insights into the binding interactions of compounds 3e and 5a with EGFR, effectively rationalizing the observed SAR trends.
- | erlotinib / Generic mfg.
Preclinical, Journal: Erlotinib regulates short-term memory, tau/A? pathology, and astrogliosis in mouse models of AD. (Pubmed Central) - Oct 22, 2024
Furthermore, erlotinib-treated 5xFAD mice exhibited significant downregulation of astrocyte activation, and treating PACs from 5xFAD mice with erlotinib markedly reduced cxcl10 (reactive astrocyte marker) and gbp2 (A1 astrocyte marker) mRNA levels and proinflammatory cytokine mRNA and protein levels. Taken together, our results suggest that erlotinib regulates tau/A?-induced AD pathology, cognitive function, and A?/tau-evoked astrogliosis and therefore could be a potent therapeutic drug for ameliorating AD symptoms.
- Welireg (belzutifan) / Merck (MSD)
The Potential of Rafflesia sp Extract as a Multi-target Inhibitor of Non-small Cell Lung Cancer: An in-silico Study (SAPPHIRE; B1F) - Oct 21, 2024 - Abstract #KATRDIC2024KATRDIC_431;
Taken together, our results suggest that erlotinib regulates tau/A?-induced AD pathology, cognitive function, and A?/tau-evoked astrogliosis and therefore could be a potent therapeutic drug for ameliorating AD symptoms. In addition, the compound also outperformed the binding affinity strength of the EGFR/HIF1A/FLT4/BIRC5 control drugs, namely erlotinib (
- | Journal: The m5C/m6A/m7G-related non-apoptotic regulatory cell death genes for the prediction of the prognosis and immune infiltration status in hepatocellular carcinoma. (Pubmed Central) - Oct 21, 2024
We have developed a prognostic model with m5C/m6A/m7G-related NARCD genes to predict the prognosis of HCC patients. This model can offer insights into the effectiveness of immunotherapy and chemotherapy for HCC patients.
- | Journal, Metastases: Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India. (Pubmed Central) - Oct 21, 2024
After a median follow up of 44 months, the median PFS was 13 months (95%CI 7.2-18.9) and the median OS was 17 months (95%CI 12.1-22.1) for the entire cohort. The overall response and survival for metastatic nccRCC was relatively better in comparison with published data, despite the limited number of patients treated with ICIs due to cost and access barriers.
- ||| Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Metastases: JUNIPER: A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (clinicaltrials.gov) - Oct 20, 2024
P3, N=453, Active, not recruiting, Sponsor: Eli Lilly and Company
The overall response and survival for metastatic nccRCC was relatively better in comparison with published data, despite the limited number of patients treated with ICIs due to cost and access barriers. Trial completion date: Dec 2024 --> Dec 2025
- | Cotellic (cobimetinib) / Exelixis, Roche
Journal: EGFR/MEK inhibitor therapy induces a distinct inflammatory hair follicle response that includes a collapse of immune privilege. (Pubmed Central) - Oct 20, 2024
Trial completion date: Dec 2024 --> Dec 2025 The data show that EGFRi/MEKi compromise the physiological IP of human scalp HFs and suggest that future clinical management of EGFRi/MEKi-induced folliculitis requires HF IP protection and inhibition of IL-33.
- | erlotinib / Generic mfg.
Journal: Combining lavendustin C and 5-arylidenethiazolin-4-one-based pharmacophores toward multitarget anticancer hybrids. (Pubmed Central) - Oct 19, 2024
Computational docking and in silico pharmacokinetic studies were performed and discussed. In conclusion, 14b might serve as a multitarget lead compound for further development of anticancer agents.
- | Conmana (icotinib) / Betta Pharma
Journal: Design and activity evaluation of new EGFR tyrosine kinase inhibitors containing cyclic polyamines. (Pubmed Central) - Oct 19, 2024
Compound b demonstrated slightly improved inhibition activity against PC-9 Del19/T790M/C797S (IC50?=?496.3?nM). This could provide some insights for optimizing EGFR inhibitors, particularly in the context of EGFR triple mutants.
- | erlotinib / Generic mfg., sorafenib / Generic mfg.
Journal: 'In silico' repurposing new inhibitors of EGFR and VEGFR-2 kinases via biophysical mechanisms. (Pubmed Central) - Oct 17, 2024
2C was shown to interact stably with pocket residues after MD simulation. Compound 2C may be a promising way to slow the signaling cascade of proteins that are significant contributors to the spread of cancer.Communicated by Ramaswamy H. Sarma.
- | erlotinib / Generic mfg.
Journal: Computer-aided anti-cancer drug discovery of EGFR protein based on virtual screening of drug bank, ADMET, docking, DFT and molecular dynamic simulation studies. (Pubmed Central) - Oct 17, 2024
Firstly, drug-bank was screened using the pharmacophore technique to select the ligands and Erlotinib (DB00530) was used as matrix compound...Furthermore, MD simulations for 100?ns revealed that the ligand interactions with the residues of EGFR protein were part of the essential residues for structural stability and functionality. However, DB03365 was a promising lead molecule that outperformed the reference compound in terms of performance and in-vitro and in-vivo experiments needs to validate the study.Communicated by Ramaswamy H. Sarma.
- | Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Real-World Data Presenting the Descriptive Analysis of the Use of Tyrosine Kinase Inhibitors (TKIs) Among Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Patients in Qatar: A Nationwide Retrospective Cohort Study. (Pubmed Central) - Oct 17, 2024
The EGFR-targeted and ALK-targeted therapies appear to have acceptable clinical response rate and safety profile in our population. Close and frequent monitoring of adverse events is advised to ensure a good quality of life and prevent serious complications.
- | erlotinib / Generic mfg.
Journal, Stroma: Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling. (Pubmed Central) - Oct 16, 2024
Last, HCM-causing MYBPC3-variant CMTs also demonstrated increased stromal activation and reduced contractility, but with distinct characteristics. Together, these findings establish a paracrine-mediated cross-talk potentially responsible for fibrotic changes observed in HCM.
- erlotinib / Generic mfg.
EVALUATION OF HIV-INDUCED LIVER INFLAMMATION AND FIBROSIS USING A NOVEL EX VIVO HUMAN LIVER MODEL () - Oct 15, 2024 - Abstract #AASLD2024AASLD_2698;
Together, these findings establish a paracrine-mediated cross-talk potentially responsible for fibrotic changes observed in HCM. These data suggest that PCLS is a novel and robust ex vivo human liver model to evaluate HIV-induced liver inflammation and fibrosis, which are in line with the principles of Replacement, Reduction and Refinement (3Rs).
- | Cyramza (ramucirumab) / Eli Lilly
Journal: Ramucirumab-induced ascites with endothelial growth factor receptor mutation-positive non-small cell lung cancer: Two case reports. (Pubmed Central) - Oct 15, 2024
Ramucirumab administration can cause ascites due to increased hepatic sinusoidal pressure. Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it.
- | erlotinib / Generic mfg.
Journal: Erlotinib-induced blepharitis: Management of two challenging cases. (Pubmed Central) - Oct 13, 2024
Clinicians should be aware of RAM-induced ascites in patients with NSCLC and should appropriately manage it. No abstract available
- Cyramza (ramucirumab) / Eli Lilly
RELAY: Final OS data with the combination of erlotinib + ramucirumab vs. placebo in untreated, EGFR-mutated metastatic NSCLC (mNSCLC) (Lima) - Oct 13, 2024 - Abstract #DGHO2024DGHO_1491;
P3
The ERL+RAM arm demonstrated numerically greater improvement in mOS compared with the ERL+PBO arm. Pts with an L858R mutation derive more modest OS with EGFR-TKI monotherapy than pts with Exon 19del, and may benefit from treatment intensification with ramucirumab.
- | erlotinib / Generic mfg.
Journal: Discovery of new sulfonamide-tethered 2-aryl-4-anilinoquinazolines as the first-in-class dual carbonic anhydrase and EGFR inhibitors. (Pubmed Central) - Oct 12, 2024
Pts with an L858R mutation derive more modest OS with EGFR-TKI monotherapy than pts with Exon 19del, and may benefit from treatment intensification with ramucirumab. Also, 10b shined as a potent and selective EGFR inhibitor, boasting an impressive IC50 value of 51.2
- Avastin (bevacizumab) / Roche
Fumarate Hydratase-Deficient Renal Cell Carcinoma () - Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5217;
It may associated with RCC FH deficient. Its rare disease very invasive .in young age with RCC advised to investigate for FH deficiency as possible cause..
- Tagrisso (osimertinib) / AstraZeneca, Gilotrif (afatinib) / Boehringer Ingelheim, Vizimpro (dacomitinib) / Pfizer
CLINICAL CHARACTERISTICS, MOLECULAR PROFILE AND TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATED NON-SMALL CELL LUNG CANCER IN SARAWAK () - Oct 11, 2024 - Abstract #ASCOMOS2024ASCOMOS_213;
CONCLUSION EGFR+ lung cancer is the most common oncogene driven lung cancer with prevalence of 50% among NSCLC. Our study showed that access to first generation TKI was high but limited for 3rd generation TKI.
- | onalespib (AT13387) / Otsuka
Trial completion date, Metastases: Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer (clinicaltrials.gov) - Oct 8, 2024
P1/2, N=11, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Our study showed that access to first generation TKI was high but limited for 3rd generation TKI. Trial completion date: Sep 2024 --> Sep 2025
- | erlotinib / Generic mfg.
Journal: Bioinspired thiazolo-[2,3-b] quinazolin-6-one derivatives as potent anti-cancer agents targeting EGFR: their biological evaluations and in silico assessment. (Pubmed Central) - Oct 3, 2024
The free binding energy (?G) of the 4bi molecule was found comparable to Erlotinib drug. The test molecule could be competent for further usage to determine its efficicacy in cancer therapeutics.
- | erlotinib / Generic mfg., gefitinib / Generic mfg.
Journal: EGFR inhibits TNF-?-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401. (Pubmed Central) - Oct 2, 2024
Physiologically, in mouse models, EGF treatment mitigates TNF-?-dependent necroptotic skin inflammation induced by treatment with IAP and caspase inhibitors. Our study revealed a novel role for EGFR in directly regulating TNF-?-related pathways.
- | MK-2206 / Merck (MSD), Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, Metastases: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies (clinicaltrials.gov) - Oct 1, 2024
P2, N=647, Completed, Sponsor: National Cancer Institute (NCI)
Our study revealed a novel role for EGFR in directly regulating TNF-?-related pathways. Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024